

Taming the Master: SWI/SNF chromatin remodeler as a therapeutic target in cancer

Murali Dharan Bashyam^{1a}, Srinivas Animireddy^{1,2*} and Pratyusha Bala^{1,2*}

¹Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Inner Ring Road, Uppal, Hyderabad 500039; ²Graduate Studies, Manipal Academy of Higher Education, Manipal, Karnataka, India

*Equal contribution

^aTo whom correspondence should be addressed:

Laboratory of Molecular Oncology, Centre for DNA Fingerprinting and Diagnostics, Inner Ring Road, Uppal, Hyderabad 500039, India. Tel: 91-40-27216112; Fax: 91-40-27216006; Email: bashyam@cdfd.org.in & bashyam69@gmail.com

Abstract

Eukaryotic cells use histone modifiers and chromatin remodelers to facilitate protein DNA interactions in the nucleus; an important requisite for regulating several cardinal nuclear processes including transcription, replication, DNA repair and recombination, etc. The SWI/SNF complex is the most well studied chromatin remodeler and is conserved from yeast to mammals. The complex is recruited to specific DNA sites where it uses energy from ATP hydrolysis to catalyze nucleosome sliding or histone eviction from DNA. Mutational inactivation of SWI/SNF components have been identified in neurological syndromes and in several cancers; recent deep sequencing studies have revealed a SWI/SNF mutation frequency of 20% in cancer genomes. In addition to mutations in tumor samples, extensive studies on cell lines and animal models have revealed tumor suppressive features for many individual SWI/SNF components. Thus, components of the complex are classified as tumor suppressors. Interestingly however, a majority of mutations do not cause inactivation of the complex, leaving behind a ‘residual’ complex that can be targeted for therapy. In addition, characterization of multiple roles of SWI/SNF components has revealed several therapeutic options. The current review summarizes the multi-faceted therapeutic opportunities for tumors bearing mutations in genes encoding SWI/SNF components.

Key words: SWI/SNF; chromatin remodeler; ARID1A; therapeutic targeting

Importance of the work: Efforts are ongoing for past few decades to develop efficient therapeutic options for cancers where conventional treatments including surgery and chemo/radiation have failed miserably. It is now well understood that tumors harbor genetic lesions that are essential for their sustenance and therefore provide an attractive target for therapy. An alternative approach is to target specific weaknesses in tumor cells that arise due to

mutations in specific genes. This review attempts to discuss several such vulnerabilities that may exist in tumor cells harboring mutations in genes encoding components of the SWI/SNF chromatin remodeling complex.

Introduction

The nucleus of a human cell harbors approximately 2m long double stranded genomic DNA containing 3.3 billion base pairs that are highly compacted to fit inside a 5-10 micron nuclear compartment. In order to achieve this density, DNA is condensed and tightly packed into a structure we call chromatin. Nucleosome, the basic unit of condensed chromatin, includes 146 base pairs of DNA tightly wrapped around a specialized protein structure formed by an octamer of histone proteins. Each histone octamer is composed of two copies each of histones H4, H3, H2A, and H2B. The wrapped DNA contacts the histone octamer through various types of noncovalent interactions. The nucleosomal structure provides stability and compactness besides facilitating protection of the genome. However, this arrangement places a huge constraint on proteins that depend on sequence specific binding to DNA for regulating various nuclear processes such as replication, transcription, DNA repair, recombination, etc^{1,2}. Hence, the chromatin state has to be dynamic, with an inherent ability to switch between a tightly packed and a more 'loosened' state; the latter facilitating binding of proteins to DNA.

Eukaryotic cells employ several mechanisms to covalently modify histones and/or DNA to regulate spatio-temporal accessibility of proteins to DNA. In addition, energy dependent processes are put in place to facilitate a 'loose' or 'open' chromatin structure, catalysed by chromatin-remodelling enzymes. Histone modifying enzymes catalyse an array of post translational modifications on the C terminal tail of histones enabling a change in the active state of chromatin by the recruitment of specific effector proteins. Chromatin remodelling enzymes on the other hand catalyse the uncoupling of DNA - histone contacts through nucleosome sliding, eviction, or replacement of canonical histones with histone 'variants' in an ATP dependent

manner, thereby exposing underlying DNA sequences (enhancers, promoters, replication origins, sites of DNA recombination or damage) to sequence specific regulators³. The ATP-dependent chromatin remodeling enzymes are remarkably diverse and genome-wide binding studies have revealed about 20-40000 sites⁴ indicating the huge abundance of the complexes in the cell. A typical chromatin remodeler is a multi-subunit assembly consisting of a core ATPase subunit that uses ATP hydrolysis to mobilize nucleosomes. In addition, several (up to 20) non-catalytic protein subunits may be present to provide structural stability to the complex as well as to impart specificity through interactions with other proteins or complexes. ATP-dependent chromatin remodelers identified till date are categorised into four families based on shared structural or functional domains: 1) SWI/SNF (switch/sucrose non-fermenting, 2) ISWI (imitation-switch), 3) NURD/CHD (chromodomain helicase DNA-binding), and 4) INO80 (inositol-requiring 80). The four complexes function in a non-redundant manner to influence discrete DNA dependent molecular functions. Dysfunction of chromatin remodelers is strongly associated with various developmental defects. More importantly, genetic alterations or aberrant expression of chromatin remodelers have been identified as possible oncogenic drivers in numerous cancers types.

The multi sub unit SWI/SNF chromatin remodelling complex

The SWI/SNF complex was the first ATP-dependent chromatin remodeler to be identified in the budding yeast *Saccharomyces cerevisiae* from two independent genetic screens and is the most well characterized till date. The screens revealed genes as transcription co-activators required for regulating mating type switching (SWI)⁵ and sucrose fermentation (Sucrose Non-Fermenting/SNF)⁶. Biochemical purification studies showed that the encoded proteins numbering about 9-12 physically associated to form a relatively large multi-subunit complex that exhibited ATP-

dependent nucleosome remodelling activity *in vitro*^{7, 8}. Further studies led to identification of additional evolutionarily conserved homologous complexes in *S. cerevisiae* (the RSC complex⁹). More importantly, a screen for identifying genes opposing the activation of Homeobox genes by the Polycomb complex in *Drosophila melanogaster* yielded similar complexes (BAP and PBAP^{10, 11}) and further studies identified counterparts in mammals (the BRG1/ BRM -associated factor (BAF) complex¹² and the polybromo BRG1-associated factor (pBAF) complex¹³) (Table 1).

The mammalian SWI/SNF complex is the primary chromatin remodeler for almost all stages of embryonic development¹⁴ as well as for differentiation of various cell types during adult life¹⁵⁻¹⁷. Various proteins that constitute the mammalian SWI/SNF complex can be classified into three categories namely a) enzymatic subunits having catalytic ATPase activity including the Brahma homologue (BRM, encoded by *SMARCA2*) and BRM-related gene 1 (BRG1, encoded by *SMARCA4*), b) set of highly conserved 'core' subunits (SNF5 (also known as, INI1 or BAF47 encoded by *SMARCB1*), BAF155 and BAF170) and c) accessory subunits that may contribute towards complex specificity (ARID1A/ARID1B, ARID2, etc.). Recently, a third SWI/SNF complex called non-canonical BAF (ncBAF, also termed GBAF) was identified that contains GLTSCR1/ GLTSCR1L instead of the ARID-domain containing proteins^{18, 19}.

Only a set of four subunits (BRG1/SMARCA4, SNF5/SMARCB1, BAF155/SMARCC1, and BAF170/SMARCC2) in humans is necessary and sufficient to perform chromatin remodeling *in vitro*²⁰. However, additional subunits may play a crucial role in binding of complex with chromatin (for example, recognition of acetylated-Lysine by components harboring the Bromo

domain) or with transcription factors. Targeting of the complex to specific gene loci is facilitated by the heterogeneity in subunit composition that can manifest differently in different tissues or at different cell states in the same tissue.

Diversity in mammalian SWI/SNF complex composition ensures varied functions

The size of the BAF complex is estimated to be about 2 MDa making it one of the largest protein complexes in the mammalian cell. The mammalian complex is substantially more diverse and multifaceted than the one initially discovered in yeast as it is encoded by at least 29 different genes suggesting the possibility of assembling a multitude of complexes through combinatorial association. BRG1 or BRM, the two subunits that exhibit ATPase activity, are always present in different SWI/SNF complexes. In addition, the complex comprises three mutually exclusive DNA binding subunits namely the AT-rich interaction domain 1A (ARID1A/BAF250a), ARID1B (BAF250b) or ARID2. ARID1A/ARID1B constitute disjoint components (paralogs) of the BAF (BRG1/BRM associated factor) complex¹² whereas ARID2 (BAF180) is a component of the pBAF complex¹³, so named because of presence of the exclusive PBRM1 subunit¹¹. In addition, BRG1 can be present in both BAF and pBAF complexes while BRM is found only in the BAF complex²¹. The recently identified ncBAF complex harbors either GLTSCR1 or GLTSCR1L instead of ARID1A/ARID1B or ARID2 besides either of the two ATPase subunits BRG1 or BRM. The SWI/SNF complex can therefore be broadly classified into three types namely BAF, pBAF and ncBAF. Several components of the SWI/SNF are encoded by gene families, whose protein products are known to assemble during complex formation in a mutually exclusive fashion despite exhibiting significant similarity in their respective amino acid

composition. The general rule for differential complex formation therefore appears to be that specific position of a subunit in the complex is occupied by any one of the family members (paralogs; position of BAF60 for example can be occupied by any one of three alternatives BAF60a, b, or c). The mutual exclusivity in SWI/SNF subunit association is touted as a major mechanism that could in principle give rise to a variety of distinct complexes with differential activities. The alternating subunits cause differential activity as they perhaps project different interacting motifs. Indeed, the subunits of SWI/SNF are known to have various protein–protein and protein-DNA interaction domains including the LXXLL motif, the PHD domain, chromodomains, binding domains that recognize specific DNA structures or AT-rich sequences and domains important for recognizing histone marks (like the Bromodomain). The diversity in SWI/SNF subunit composition may mediate the interaction with specific transcription factors and/or modified histones allowing the recognition of specific target gene sets to regulate distinct functions. The ability of BRG1 and BRM for example to have distinct transcriptional specificity despite an overall amino acid identity of ~70% is due to N terminal amino acid sequence variation which allows the interaction with distinct transcription factors²². Similarly, ARID1A and ARID1B are mutually exclusive paralogous subunits sharing 60% amino acid sequence identity but regulate distinct functions^{23, 24}. The recently identified ncBAF/GBAF complex harbors BRD9, a paralog of the bromodomain containing BRD7, that regulates gene sets distinct from that of other BAF and pBAF complexes^{18, 25}. Re-configuration of SWI/SNF composition has been shown to be important during developmental processes especially for lineage specification. For example, the BAF53A and BAF45A subunits are replaced by BAF45B/BAF45C and BAF53B, respectively during differentiation of neural stem cells into mature neurons²⁶. Similarly, SWI/SNF containing BAF60a (encoded by *SMARCD1*) promotes

transcription of Oct4 and Sox2⁴, while the complex harboring BAF60b (encoded by *SMARCD2*) regulates granulocyte differentiation²⁷ and the complex comprising BAF60c (encoded by *SMARCD3*) promotes cardiac and skeletal muscle development²⁸.

SWI/SNF in disease

The SWI/SNF complex plays an essential role in epigenetic regulatory mechanisms that impact several developmental processes¹. Given the fundamental nature of SWI/SNF function, it is but natural to expect the malfunctioning or loss of its subunits to be associated with disease conditions. Of the four distinct mammalian chromatin remodelers (SWI/SNF, ISWI, CHD, INO80), inactivation of SWI/SNF subunits is strongly implicated in various diseases. Indeed, mutations and other forms of genetic lesions in genes encoding SWI/SNF components cause various familial syndromes, multi-system developmental disorders specially related to neuro-development and several types of cancers.

Neuro-developmental disorders

The SWI/SNF orchestrates various pre- and post-natal neural developmental events besides performing a cardinal role in proliferation of neuronal stem cells²⁹. More importantly, conditioned ablation of BAF155 and BAF170 core subunits causes severe defects in development of forebrain and related structures³⁰ as well as defects in cerebral cortical size and structure³¹ in mice. Based on these observations, alterations and mutations in its components can be expected to cause neuro-developmental defects. Indeed, mutations in several components of the SWI/SNF complex have been reported in intellectual disability syndromes^{8,9}. Inactivating

mutations in ARID1A, ARID1B, ARID2, SMARCA2, SMARCA4, SMARCB1 and SMARCE1 were reported in Coffin–Siris syndrome¹⁰. Similarly, missense mutations in SMARCE1, SMARCC1 and SMARCC2 were identified in autism spectrum disorders^{11,12} and mutations in SMARCA2 were detected in patients with Nicolaides-Baraitser syndrome³². During the past decade, mutations in several genes encoding SWI/SNF components have been described to be causal to neurological syndromes; the information is summarized in Table 1a.

Human Cancers

More than eleven genes coding various components of the SWI/SNF have been reported to be altered in various cancers (Table 1b). The alterations include missense mutations, gene fusions, copy number variations, epigenetic silencing and even overexpression in some cases. The association of SWI/SNF complexes with cancer was first reported in the late 1990s; bi-allelic inactivation of *SMARCB1* was identified in the lethal childhood sporadic cancer called Rhabdoid Tumors (RT)³³⁻³⁵. Germline inactivation of *SMARCB1* predisposed patients to RTs³⁶ and a second somatic mutation resulted in full blown disease. The cardinal role of *SMARCB1* in causing RT was confirmed in mice studies; mono-allelic inactivation or conditional ablation causes aggressive rhabdoid-like tumors and Tcell lymphomas^{17,18} whereas a bi-allelic loss resulted in rapid embryonic lethality (as early as 3.5 to 5.5 days post- coitum)¹⁶. Various types of genetic lesions that inactivate genes encoding various SWI/SNF components including ARID1A, BRG1, ARID1B, BRM, etc. in a wide variety of cancers are described below.

Mutations

Deep sequencing studies performed over the past decade or so has revealed frequency of mutations in SWI/SNF components in human cancers to be about 20%^{37, 38}. We analyzed the mutation frequency of SWI/SNF in various cancers from the MSK-IMPACT Clinical Sequencing Cohort³⁹; the complex was found to be altered in 2150 of 10336 (19.6%) tumor samples, accessed through the cBioPortal (Figure 1), inferring that proper functioning of the polymorphic BAF and pBAF complexes could be a major mechanism of tumor suppression. The various components of SWI/SNF complex reported to be mutated or altered in human cancers are listed in Table 1b. Of the many components, ARID1A, SMARCA4 and SMARCB1 exhibit a significantly higher frequency of mutation in cancers. In addition, several subunits exhibit high frequency of mutational inactivation in specific cancer types while harboring very low or nil mutations in other cancers. For example, *SMARCB1* and *PBRM1* exhibit a mutation frequency of 95% and 40% in Rhabdoid tumors and renal clear cell carcinoma respectively but are rarely mutated in other cancers⁴⁰. Unlike classical homozygous tumor suppressor events, most SWI/SNF somatic mutational events are mono-allelic indicating a dosage sensitivity or a dominant effect. Only exception is the bi-allelic inactivation of *SMARCB1* in RTs, wherein the effect is akin to a classical tumor suppressor.

Epigenetic silencing

RTs are characterized by a remarkable genetic stability as the tumors exhibit a very low mutation rate; the primary mechanism of carcinogenesis appears to be loss of epigenetic control mediated

by the SWI/SNF on the *CDKN2A* tumor suppressor loci. Thus, RT is perhaps one of the first examples of a cancer arising purely due to a genetic defect that manifests at the epigenetic level. In addition to inactivating mutations, other underlying mechanisms, such as epigenetic silencing through nucleosome remodeling, methylation of histones and DNA, also contribute to the inactivation or loss of function of chromatin remodelers in human cancer. For example, the BRM gene is inactivated in adult lung⁴¹, breast, ovary, bladder and esophagus cancers, and pediatric rhabdoid tumors through epigenetic silencing by DNA methylation, promoter mutations and other non-mutation modes⁴². In addition, BAF250B exhibits significantly reduced or loss of expression in pancreatic cancer cell lines⁴³ because of promoter hyper methylation.

How does SWI/SNF perturbation drive oncogenesis?

As mentioned above, the SWI/SNF family of chromatin remodelers regulate several cardinal cell processes including transcription, DNA repair and recombination, cell cycle, cell death or survival, differentiation and genomic stability. These could be a direct effect of faulty remodeling of chromatin or an indirect effect of deregulated expression of target genes. Since these processes are expected to be cardinal for tumor suppression and given that SWI/SNF appears to have an extensive footprint across the mammalian genome, it is likely to be involved directly or indirectly in several tumorigenic processes. Earlier studies have elucidated SWI/SNF directed gene expression programs regulating specific pathways and how mutation in SWI/SNF components promotes cancer. SWI/SNF was shown to interact with both Rb (a tumor suppressor)⁴⁴ and MYC (an oncogene)^{24, 45} leading to perturbations of genes controlled by these master regulators. The complex also binds to and regulates transcriptional program controlled by

p53⁴⁶. In fact, p53 appears to depend on interaction with SWI/SNF components BAF60a/SMARCD1⁴⁷, SNF5/INI1⁴⁸, ARID1A/SMARCF1⁴⁹ and BrG1/SMARCA4⁵⁰ to activate its target genes. Thus, SWI/SNF appears to be an important component of the tumor suppressor function performed by p53. Several reports revealed multi-faceted effect of SWI/SNF on cell cycle progression. Through its interaction with Rb, SWI/SNF regulates transcription of p16 and E2F targets⁵¹. SWI/SNF induces expression of additional cell cycle regulating and senescence inducing genes such as p21^{43, 52, 53} and p53⁵³ besides being an important mediator of the cell cycle regulation performed by TGF- β signaling^{54, 55}.

A major role of SWI/SNF in regulating tumorigenesis appears to emanate from its antagonistic action on the PRC2/EZH2 (Polycomb group) complex⁵⁶. One of the strongest associations of a SWI/SNF component with tumorigenesis is that of SMARCB1/INI1/SNF5 with RTs.

Interestingly, the mechanistic link of SMARCB1 inactivation with tumorigenesis appears to act primarily through antagonism with PRC2/EZH2 mediated histone H3K27 tri methylation⁵⁷.

Several additional mechanisms including activation of cyclin D1, perturbation of sonic hedgehog and Wnt signaling have also been proposed^{57, 58}. Loss of BRG1 promotes tumor aggressiveness in primary and established lung cancer cell lines through perturbations in global chromatin architecture especially in gene loci pertinent for the disease⁵⁹.

Though initial studies focused on evaluating role of SWI/SNF at or near promoters to facilitate transcription initiation by RNA polymerase II⁶⁰, work during past few years have provided evidence for their requirement at enhancers especially pertaining to their role in cancers.

SWI/SNF appears to bind to and recruit CBP/p300 histone acetyl transferase at regular (not

super) enhancers especially related to genes important for lineage specification^{61, 62} and the complex also regulates enhancers that function to establish and maintain cell identity^{63, 64}. The enhancer regulation property of SWI/SNF appears to play a major role in tumorigenesis as well. Genetic knockout of ARID1A in the mouse colon causes colon cancers through loss of ARID1A containing SWI/SNF activity on enhancers. ARID1B containing complexes however maintain activity of a distinct set of enhancers⁶⁵, probably required for tumor sustenance. Similarly, RTs caused by SMARCB1 also emanate from a loss of function of enhancers related to lineage specific function but not of super-enhancers whose activity is essential for survival of the tumor⁶⁶. Thus, loss of SWI/SNF leads to de-activation of enhancers driving lineage and differentiation related genes, perhaps resulting in de-differentiation and a proliferative phenotype.

The SWI/SNF pBAF complex is known to play a role in regulating repair of DNA double strand breaks by promoting transcription repression and this activity is dependent on Ataxia telangiectasia mutated (ATM)⁶⁷. More recently, it was shown that inhibition of pBAF mediated transcription repression led to increased chromosomal re-arrangements suggesting a possible role in promoting tumorigenesis⁶⁸.

Therapeutic options in tumors harboring genetic lesions in SWI/SNF components

About two decades ago, several laboratories began to work towards developing targeted therapies given the poor success achieved with conventional therapies like radiation and chemotherapy. Years of research has yielded targeted therapies with significant success against

oncogenic events in specific cancers such as the HER2 amplification in breast cancer (Herceptin/Trastuzumab)⁶⁹, oncogenic gain of function mutation in EGFR (lung cancer)⁷⁰⁻⁷², *ALK* gene rearrangements (also in lung cancer)⁷³, and a few others. Despite the initial success, most targeted therapies encountered resistance in a significant proportion of patients and addressing this issue is a major research focus in laboratories the world-over. In addition, efforts were also initiated towards other modes of targeted therapies. One such approach focused on determining vulnerabilities in tumor cells arising out of specific genetic lesions.

Targeting vulnerabilities arising from inactivation of tumor suppressive SWI/SNF

As already described, inactivating mutations in a SWI/SNF component appears to occur in about 20% of all cancers. It was initially thought that genetic lesions in different SWI/SNF components in different cancers had a similar effect on tumorigenesis emanating from inactivation of SWI/SNF function. However, additional observations provided evidence against identical action of various mutations. Firstly, ablation of each component is usually associated with one or a few unique cancer types. For example, loss of *ARID1A* is common in ovarian cancer^{74, 75}, that of *SMARCA4* in lung cancer⁷⁶ and of *SMARCB1* in RTs⁷⁷; this specificity of individual SWI/SNF subunits has also been validated in mouse models^{35, 78}. Secondly, mouse knockout studies revealed a distinct phenotype for each SWI/SNF component tested. For example, *SMARCB1* and *SMARCA4* knockouts were embryonic lethal^{79, 80} whereas that of *SMARCD3* resulted in abnormal cardiac development⁸¹.

Inactivation of one SWI/SNF component/complex generates synthetic lethality in another

Wang and colleagues mooted the idea whether the differential behavior emanating from inactivation of each component could result from differential activity of the residual complex which in turn could be crucial for tumor cell survival⁸². They tested this hypothesis by ablating *SMARCA4* (which encodes the ATPase subunit BRG1) in the background of *SMARCB1* loss and the results indeed revealed a dependency of *SMARCB1* ablated cells on *SMARCA4*. Thus, *SMARCA4* loss is synthetic lethal with *SMARCB1* ablation and can be utilized as a therapeutic target. Though the authors proposed that the residual BAF complex could be important for oncogenic potential of the tumor cell, it is possible that this dependency was due to action of the pBAF complex that incorporates BRG1 as the only ATPase subunit; a possibility not considered by the authors. Nevertheless, this observation plus the fact that a) previous studies showed that the complex could be assembled even in the absence of one component^{83, 84} and b) the SWI/SNF complex is the most important chromatin remodeler during ontogeny and adult life, led to several initiatives directed towards identifying genes that could be synthetic lethal with other inactivated SWI/SNF components. In such a screen, a cancer cell line harboring inactivation of one SWI/SNF component is used to generate a library of clones each harboring inactivation of one additional gene; the clones are evaluated for any one of several tumorigenic characteristics (such as survival, growth rate, viability, cell motility/migration, etc.). These screens interestingly revealed a synthetic lethal dependency of *ARID1A* mutant cells on *ARID1B* (loss of one ARID domain BAF subunit makes the cells dependent on the remaining one⁸⁵) as well as of *SMARCA4* inactivated cells on *SMARCA2* (loss of one ATPase subunit makes the cells dependent on the remaining one^{84, 86}). These results point to the fact that ablation of one SWI/SNF subunit does

not de-activate the whole complex as thought earlier, but the remaining complex appears to perform some function crucial for sustenance of the tumor cell. Interestingly, a large-scale proteomic analysis following individual subunit deletion in yeast did reveal presence of active residual SWI/SNF complexes⁸⁷, further supporting the results obtained in humans.

A more recent study revealed cancers with perturbation in BAF components to be dependent on ncBAF¹⁹, thus highlighting a synthetic lethal relationship between two distinct SWI/SNF complexes as against paralogs of the same complex. Perhaps perturbation of a core component (for which no paralog is available) makes the cell dependent on a distinct SWI/SNF complex. One common theme that has emerged from these studies however is that SWI/SNF complex is essential for tumor maintenance and thus the residual complex offers an excellent therapeutic option. Of course, the therapeutic target in the residual complex will differ depending on the tumor type as well as identify of the inactivated SWI/SNF component.

Vulnerabilities in PRC1/2

Another approach to identify therapeutic targets in tumors harboring SWI/SNF inactivation is based on the Polycomb Repressive Complexes (PRC1/PRC2), categorized under Polycomb Group (PcG) of proteins, that exhibit histone methyl transferase enzymatic activity which is antagonistic to the SWI/SNF and can be expected to exhibit augmented oncogenic activation in the background of SWI/SNF inactivation. Initial studies performed in *Drosophila* provided the first evidence for an antagonistic relationship between the SWI/SNF and PRC2 complexes. During initial stages of *Drosophila* development, the rapid burst of cell proliferation is primarily

driven by the activation of PcG proteins that includes the PRC1/PRC2 complex. These complexes use their inherent histone methyl transferase activity to transcriptionally silence genes belonging to the Homeobox (HOX) family. During the later stages of development, a reduction in proliferation and initiation of differentiation is triggered by the activation of the Trithorax group of proteins (including members of the SWI/SNF complex) which inhibit PRC2 inducing thereby the expression of HOX genes⁸⁸. The antagonistic relationship between the two complexes has been validated in mammals as well^{56, 89}. Based on this knowledge, it was hypothesized that RTs that arise due to inactivation of *SMARCB1* could be critically dependent on activity of the PRC2 complex; the hypothesis was tested and successfully validated by applying an EZH2 synthetic inhibitor in a mouse xenograft model for malignant rhabdoid tumors⁹⁰. Similar efforts were undertaken for tumors harboring inactivation of other SWI/SNF components. For example, ARID1A mutated ovarian cancer cells were found to be synthetic lethal for EZH2 inhibition in cell lines and mouse models^{91, 92}. More importantly, it seems fair to assume that tumors developing due to inactivation of a SWI/SNF component might be dependent on PRC2 proteins for their sustenance. However, whether this can be applicable to a broad range of cancer types is an open question. Of note, there are intrinsic differences in the PRC2-SWI/SNF antagonism between *Drosophila* and humans; the *Drosophila* BAF complex inhibits action of Polycomb proteins at the HOX locus⁹³ whereas in humans, both complexes work synergistically to place the suppressive histone H3K27 trimethylation mark on the HOX loci⁹⁴.

An interesting link between BRG1 and EZH2 was revealed in non-small cell lung cancer. Tumors harboring genetic inactivation of BRG1 were sensitive to EZH2 inhibition that resulted in increased susceptibility to TopoII inhibitors⁹⁵. However, there is a complete reversal of the

response in BRG1 wild type tumors which become resistant to TopoII inhibition upon EZH2 ablation⁹⁵. Therefore, BRG1 status appears to be an important biomarker to predict response to EZH2 and TopoII inhibition in NSCLC.

Vulnerabilities in additional non-SWI/SNF proteins/complexes

Additional screens revealed a dependency on other non-SWI/SNF genes/complexes. In an siRNA based screen for essential genes in lung cancer cells exhibiting *SMARCA4* loss, Aurora kinase A was identified suggesting importance of SWI/SNF function in centrosome independent mode of mitotic spindle assembly which is probably upregulated in lung cancer⁹⁶. Thus, SWI/SNF functions not directly related to transcriptional regulation could also be evaluated for targeted therapies in tumors exhibiting loss of one SWI/SNF component.

Screening for a gene which provides a vulnerability target for SWI/SNF mutant cancers is not the only approach employed by researchers for exploring treatment options. In a more standard approach, Deribe and colleagues decided to determine transcriptome signature to identify differential pathways in SWI/SNF mutant lung cancer. They performed a comparative transcriptome analysis between KRAS/p53 ablated tumors generated in mice and tumors generated from KRAS/P53/SMARCA4 ablation and identified genes regulating mitochondrial oxidative phosphorylation (OXPHOS) to be enriched in tumors arising out of the triple genetic event compared to KRAS/P53 ablated tumors⁹⁷. These tumors were increasingly dependent on this important mitochondrial function for their energy requirement and vulnerable to small molecular inhibitors of OXPHOS⁹⁷.

The continuing research on SWI/SNF components has revealed several (non-transcriptional) roles which may provide alternative strategies for therapeutics. A study focused on identifying binding partners of ATR, a protein involved in initiation of DNA damage response, revealed ARID1A as a binding partner. Further evaluation revealed essentiality of ARID1A for double strand break repair as well as for regulating the G2/M DNA damage checkpoint. More importantly, loss of ARID1A makes cells partially deficient for double strand break repair (similar to the situation arising due to *BRC1* mutations) and makes them vulnerable to PARP inhibitors⁹⁸. Given the earlier studies that ascribed an important role for SWI/SNF in DNA repair, the current discovery of importance of ARID1A in double strand break repair and synthetic lethality with PARP is not surprising.

Recently, another interesting link between DNA damage repair and SWI/SNF was elucidated. It was shown that SWI/SNF promotes double strand break and nucleotide excision repair not only by facilitating access of DNA repair proteins by nucleosomal remodeling but also by activating expression of GTF2H1, a component of the TFIIH complex. Interestingly however, GTF2H1 cannot be used as a synthetic lethal target under ablation of BRG1 or BRM as the cells somehow manage to retain adequate levels of GTF2H1⁹⁹. Though BRG1 levels were proposed as a marker to predict response to DNA damage based therapies such as ‘Cisplatin’, it appears that GTF2H1 levels are a better predictive biomarker. More importantly, it may be important to delineate mechanism of compensation in GTF2H1 levels upon BRG1/BRM ablation which could become a vulnerability that can be exploited for therapy.

Screening for synthetic lethality associated with ARID1A inactivation

Since ARID1A is the most frequently mutated SWI/SNF component in ovarian clear cell carcinoma (OCCC), several studies performed genetic screens to identify synthetic lethality with ARID1A mutations. An shRNA based synthetic lethal ‘kinome’ screen was performed in a large panel of OCCC cell lines which identified BRD2 as a synthetic lethal target in cell lines having mutant ARID1A which was validated in mouse xenografts derived from OCCC cell lines as well as from patient tumors¹⁰⁰. Interestingly, using chromatin immunoprecipitation, BRD2 was shown to bind to the promoter regions of several SWI/SNF genes including ARID1A, ARID1B, SMARCE1/BAF57 and SMARCC2/BAF155 suggesting perhaps that BRD2 might be involved in transcriptional activation of SWI/SNF genes. A separate functional genomics screen using anti-cancer drugs already in use, identified dasatinib as synthetic lethal with ARID1A mutation in OCCCs; dasatinib probably acts by removing the ablation of p21/Rb1 caused due to ARID1A mutation¹⁰¹. A third synthetic lethality screen using shRNAs against eleven histone deacetylases (HDACs) identified HDAC6 to be synthetic lethal with ARID1A mutation¹⁰². Interestingly, ARID1A appears to be a transcriptional repressor of HDAC6 and mutation induced ARID1A loss of expression alleviates repression of HDAC6 which in turn acts by inhibiting the apoptosis promoting function of wild type p53 through deacetylation¹⁰². A separate study based on a proteome screen to detect ARID1A binding partners revealed ARID1A binding to MSH2¹⁰³. Further, ARID1A was shown to participate in mismatch repair and ARID1A mutations were shown to increase the tumor mutation burden and production of several ‘neo-antigens’ similar to tumors arising from mismatch repair inactivation resulting in microsatellite instability. More importantly, ARID1A mutant tumors generated in syngenic mice were sensitive to immune

checkpoint therapy¹⁰³. Thus, ARID1A mutations can be used as a biomarker to predict response to immune checkpoint inhibitors.

The repertoire of cell processes where SWI/SNF (particularly the ARID1A subunit) plays a cardinal role seems to be expanding with more and more laboratories reporting new findings. A recent study revealed a unique link between SWI/SNF and the tumor suppressive cytoplasmic Hippo signaling cascade, which represses activity of the YAP/TAZ transcription factors that control cell proliferation in relation to organ size. ARID1A binds to and represses activity of YAP/TAZ. Mechanical stress induced by attainment of optimum organ size and relayed through F-actin dynamics perturbs the interaction between ARID1A and YAP/TAZ allowing functional activation of the latter through binding with TEAD¹⁰⁴. Thus, loss of SWI/SNF could potentially activate YAP/TAZ function revealing yet another therapeutic vulnerability.

Given the multiple nuclear functions of the SWI/SNF (such as DNA recombination, repair, YAP/TAZ regulation, etc.), one would expect several vulnerabilities arising from its inactivation some of which are already being evaluated for possible targeted therapies as enumerated above. In addition, the possibility of SWI/SNF components exhibiting non-SWI/SNF dependent functions(s) (such as the E3 ubiquitin ligase activity of ARID1B that targets histone H2B¹⁰⁵), provides further opportunities for possible therapeutic targeting. Indeed, we have not yet understood the complete repertoire of SWI/SNF function; work in several laboratories is ongoing in this direction and one can expect additional breakthroughs in the near future.

Direct targeting of oncogenic SWI/SNF?

Though the SWI/SNF complex is classified as a tumor suppressor, the fact that nucleosome repositioning is likely to be used by several (possibly including oncogenic) cellular processes, it should not be surprising to detect possible oncogenic roles for protein components of the complex. In addition, given the importance of SWI/SNF role in functioning of enhancers, one would expect the complex to perhaps regulate the activation of oncogenes as well. Many studies have reported components of the SWI/SNF to be widely overexpressed in human cancers, such as BRG1 and BRM in acute leukemia¹⁰⁶, colorectal cancer¹⁰⁷, prostate cancer¹⁰⁸ and primary breast cancers¹⁰⁹; BAF53a in rhabdomyosarcoma¹¹⁰ and glioma¹¹¹; BAF57 in prostate cancer¹¹²; BAF60a in gastric cancer¹¹³ and BAF155 in prostate¹¹⁴ and colorectal cancer. Leukemia cells appear to rely on BRG1 containing SWI/SNF to maintain their oncogenic status¹¹⁵ by activating the *MYC* oncogene¹⁰⁶. Another study revealed requirement of BRG1 for proliferation of breast cancer cells^{116,117} as well as for the maintenance of neuroblastoma cell viability¹¹⁸. The importance of SWI/SNF in activation of oncogenic target genes due to action of the EWSR1-FLI fusion was highlighted recently in Ewing's sarcoma¹¹⁹. The EWSR1-FLI fusion recruits SWI/SNF to specific enhancers to facilitate expression of oncogenic target genes¹¹⁹. A more recent meta-analysis study revealed BRG1 to be routinely overexpressed in several tumor types¹²⁰.

A more direct evidence for oncogenic mode of action of a mutant SWI/SNF was revealed in a study on synovial sarcomas. Synovial sarcoma is defined at the molecular level by a recurrent driver chromosomal translocation t(X;18) (p11.2;q11.2) resulting in the fusion of SS18, a

recently described component of SWI/SNF, with the related protein SSX. Interestingly, the fusion protein incorporates itself into and evicts both SS18 and the core subunit BAF47 from the SWI/SNF complex. The altered complex containing the fusion protein binds to the *SOX2* locus relieving the repressive histone H3K27 trimethylation mark thereby inducing *SOX2* expression and cell proliferation. Since the altered complex is recruited to an oncogene (here *SOX2*) the effect is a propagation of tumorigenic features^{121, 122}. Interestingly, the action of the altered complex at the *SOX2* locus is identical to that of the wild type i.e. to displace proteins of the polycomb group (here EZH2) and reduce or remove the transcriptionally repressive H3K27 trimethylation mark. These observations provide renewed evidence for the antagonism between EZH2 and SWI/SNF on many gene loci. Thus, the SS18-SSX fusion protein becomes a possible direct target for therapy in synovial sarcomas.

As described above, wild type p53 is known to utilize various SWI/SNF components including SNF5⁴⁸, BRG1⁵⁰, ARID1A⁴⁹ and BAF60a⁴⁷ to facilitate its transcriptional activation and tumor suppressor function. *TP53* is the most frequently mutated gene in human cancers and specific recurrent mutations (affecting ‘hotspot’ amino acids located in the region encoding its DNA binding domain) have been shown to exhibit an oncogenic gain of function. Though these mutant p53 forms lose their respective DNA binding activities, they are able to co-operate with other transcription factors to activate expression of oncogenes. Interestingly, several mutant p53 appears to hijack SWI/SNF components to facilitate their oncogenic functions. For example, mutant p53 was shown to cooperate with SWI/SNF to induce the expression of pro-angiogenic factor VEGFR2 in breast cancer cells¹²³. Similarly, knockdown of BRG1 was shown to induce senescence in CRC cells through a p21 and p53 dependent mechanism¹²⁴.

Classical tumor suppressor genes (TSGs) and oncogenes harbor distinct mutation pattern in tumors. TSGs often exhibit loss of function (inactivation) mutations such as nonsense or frameshift whereas mutations in oncogenes cause a gain of function and therefore they are mostly of the missense category. While loss of function mutations in SWI/SNF subunits seem to be highly prevalent in cancer, missense mutations have also been described^{125, 126}. It is unclear whether these point mutations result in complete or partial loss of function or potentially an oncogenic gain of function. The preliminary observations enumerated above highlight a possible oncogenic action of SWI/SNF components and could be a prelude to additional discoveries. Future work in this direction may thus reveal whether an oncogenic function of SWI/SNF components could be targeted for therapy in specific tumors.

Concluding remarks

Decades of research have revealed SWI/SNF to be a master regulator of chromatin dynamics impinging on several cardinal nuclear processes. More importantly, it is one of the most frequently mutated protein complexes in cancer. Despite this, we still know very little about mechanism of the multi protein complex in regulating fundamental nuclear processes or tumorigenesis. It is unclear why unlike classical tumor suppressors, SWI/SNF components do not exhibit bi-allelic mutations (with *SMARCB1* being the only exception). It is possible that genes encoding SWI/SNF components are essential and a bi-allelic mutation is lethal (as shown with mice knockout studies) whereas a mono-allelic mutation disrupts the complex due to a dosage effect.

Of note, the susceptibility of a tumor cell harboring inactivating mutation in a SWI/SNF subunit could emanate from activity of the residual complex or vulnerability of an un-related function or from the activation of an oncogenic function originally suppressed by SWI/SNF. In contrast, there is also evidence of some cancer types hijacking a possible oncogenic function of SWI/SNF components. It will be important to design therapies based on these contrasting features differing from tumor to tumor and patient to patient, paving the way for therapeutic regimes tailor made for each cancer type and each patient, what is popularly known as 'Precision Medicine'. Recent findings have increased our basic knowledge of these mechanisms and revealed unique therapeutic options arising from inactivation of individual SWI/SNF components. Moving forward, furthering our understanding of the basic roles of wild type and mutated SWI/SNF will likely reveal additional therapeutic options for cancer types critically dependent on SWI/SNF function.

Acknowledgements

The work was supported by a grant (BT/PR13948/BRB/10/1406/2015) from the Department of Biotechnology, Government of India to MDB. SA and PB, registered PhD students of Manipal Academy of Higher Education, Manipal, Karnataka, India, are grateful to the Department of Science and Technology, Government of India, and the University Grants Commission, Government of India, respectively, for junior and senior research fellowships.

References

1. Narlikar, G.J., Fan, H.Y. and Kingston, R.E., Cooperation between complexes that regulate chromatin structure and transcription. *Cell*, 2002, **108**, 475-487.
2. Wilson, B.G. and Roberts, C.W., Swi/snf nucleosome remodellers and cancer. *Nat Rev Cancer*, 2011, **11**, 481-492.
3. Saha, A., Wittmeyer, J. and Cairns, B.R., Chromatin remodelling: The industrial revolution of DNA around histones. *Nat Rev Mol Cell Biol*, 2006, **7**, 437-447.
4. Ho, L., Jothi, R., Ronan, J.L., Cui, K., Zhao, K. and Crabtree, G.R., An embryonic stem cell chromatin remodeling complex, esbaf, is an essential component of the core pluripotency transcriptional network. *Proc Natl Acad Sci U S A*, 2009, **106**, 5187-5191.
5. Stern, M., Jensen, R. and Herskowitz, I., Five swi genes are required for expression of the ho gene in yeast. *J Mol Biol*, 1984, **178**, 853-868.
6. Neigeborn, L. and Carlson, M., Genes affecting the regulation of suc2 gene expression by glucose repression in *saccharomyces cerevisiae*. *Genetics*, 1984, **108**, 845-858.
7. Cairns, B.R., Kim, Y.J., Sayre, M.H., Laurent, B.C. and Kornberg, R.D., A multisubunit complex containing the swi1/adr6, swi2/snf2, swi3, snf5, and snf6 gene products isolated from yeast. *Proc Natl Acad Sci U S A*, 1994, **91**, 1950-1954.
8. Cote, J., Quinn, J., Workman, J.L. and Peterson, C.L., Stimulation of gal4 derivative binding to nucleosomal DNA by the yeast swi/snf complex. *Science*, 1994, **265**, 53-60.
9. Cairns, B.R., Lorch, Y., Li, Y., Zhang, M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Du, J., Laurent, B. and Kornberg, R.D., Rsc, an essential, abundant chromatin-remodeling complex. *Cell*, 1996, **87**, 1249-1260.
10. Collins, R.T., Furukawa, T., Tanese, N. and Treisman, J.E., Osa associates with the brahma chromatin remodeling complex and promotes the activation of some target genes. *EMBO J*, 1999, **18**, 7029-7040.
11. Mohrmann, L., Langenberg, K., Krijgsveld, J., Kal, A.J., Heck, A.J. and Verrijzer, C.P., Differential targeting of two distinct swi/snf-related drosophila chromatin-remodeling complexes. *Mol Cell Biol*, 2004, **24**, 3077-3088.
12. Wang, W., Cote, J., Xue, Y., Zhou, S., Khavari, P.A., Biggar, S.R., Muchardt, C., Kalpana, G.V., Goff, S.P., Yaniv, M., Workman, J.L. and Crabtree, G.R., Purification and biochemical heterogeneity of the mammalian swi-snf complex. *EMBO J*, 1996, **15**, 5370-5382.
13. Yan, Z., Cui, K., Murray, D.M., Ling, C., Xue, Y., Gerstein, A., Parsons, R., Zhao, K. and Wang, W., Pbf chromatin-remodeling complex requires a novel specificity subunit, baf200, to regulate expression of selective interferon-responsive genes. *Genes Dev*, 2005, **19**, 1662-1667.
14. Elfring, L.K., Daniel, C., Papoulas, O., Deuring, R., Sarte, M., Moseley, S., Beek, S.J., Waldrip, W.R., Daubresse, G., DePace, A., Kennison, J.A. and Tamkun, J.W., Genetic analysis of brahma: The drosophila homolog of the yeast chromatin remodeling factor swi2/snf2. *Genetics*, 1998, **148**, 251-265.
15. de la Serna, I.L., Carlson, K.A. and Imbalzano, A.N., Mammalian swi/snf complexes promote myod-mediated muscle differentiation. *Nat Genet*, 2001, **27**, 187-190.
16. Gresh, L., Bourachot, B., Reimann, A., Guigas, B., Fiette, L., Garbay, S., Muchardt, C., Hue, L., Pontoglio, M., Yaniv, M. and Klochendler-Yeivin, A., The swi/snf chromatin-remodeling complex subunit snf5 is essential for hepatocyte differentiation. *EMBO J*, 2005, **24**, 3313-3324.
17. Pedersen, T.A., Kowenz-Leutz, E., Leutz, A. and Nerlov, C., Cooperation between c/ebpalpha tbp/tfiib and swi/snf recruiting domains is required for adipocyte differentiation. *Genes Dev*, 2001, **15**, 3208-3216.
18. Alpsy, A. and Dykhuizen, E.C., Glioma tumor suppressor candidate region gene 1 (gltscr1) and its paralog gltscr1-like form swi/snf chromatin remodeling subcomplexes. *J Biol Chem*, 2018, **293**, 3892-3903.

19. Michel, B.C., D'Avino, A.R., Cassel, S.H., Mashtalir, N., McKenzie, Z.M., McBride, M.J., Valencia, A.M., Zhou, Q., Bocker, M., Soares, L.M.M., Pan, J., Remillard, D.I., Lareau, C.A., Zullo, H.J., Fortoul, N., Gray, N.S., Bradner, J.E., Chan, H.M. and Kadoch, C., A non-canonical swi/snf complex is a synthetic lethal target in cancers driven by baf complex perturbation. *Nat Cell Biol*, 2018, **20**, 1410-1420.
20. Phelan, M.L., Sif, S., Narlikar, G.J. and Kingston, R.E., Reconstitution of a core chromatin remodeling complex from swi/snf subunits. *Mol Cell*, 1999, **3**, 247-253.
21. Hargreaves, D.C. and Crabtree, G.R., Atp-dependent chromatin remodeling: Genetics, genomics and mechanisms. *Cell Res*, 2011, **21**, 396-420.
22. Kadam, S. and Emerson, B.M., Transcriptional specificity of human swi/snf brg1 and brm chromatin remodeling complexes. *Mol Cell*, 2003, **11**, 377-389.
23. Raab, J.R., Resnick, S. and Magnuson, T., Genome-wide transcriptional regulation mediated by biochemically distinct swi/snf complexes. *PLoS Genet*, 2015, **11**, e1005748.
24. Nagl, N.G., Jr., Wang, X., Patsialou, A., Van Scoy, M. and Moran, E., Distinct mammalian swi/snf chromatin remodeling complexes with opposing roles in cell-cycle control. *EMBO J*, 2007, **26**, 752-763.
25. Mashtalir, N., D'Avino, A.R., Michel, B.C., Luo, J., Pan, J., Otto, J.E., Zullo, H.J., McKenzie, Z.M., Kubiak, R.L., St Pierre, R., Valencia, A.M., Poynter, S.J., Cassel, S.H., Ranish, J.A. and Kadoch, C., Modular organization and assembly of swi/snf family chromatin remodeling complexes. *Cell*, 2018, **175**, 1272-1288 e1220.
26. Lessard, J., Wu, J.I., Ranish, J.A., Wan, M., Winslow, M.M., Staahl, B.T., Wu, H., Aebersold, R., Graef, I.A. and Crabtree, G.R., An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron*, 2007, **55**, 201-215.
27. Priam, P., Krasteva, V., Rousseau, P., D'Angelo, G., Gaboury, L., Sauvageau, G. and Lessard, J.A., Smarcd2 subunit of swi/snf chromatin-remodeling complexes mediates granulopoiesis through a cebpvarepsilon dependent mechanism. *Nat Genet*, 2017, **49**, 753-764.
28. Puri, P.L. and Mercola, M., Baf60 a, b, and cs of muscle determination and renewal. *Genes Dev*, 2012, **26**, 2673-2683.
29. Taverna, E.G., M; Huttner, W. B., The cell biology of neurogenesis: Toward an understanding of the development and evolution of the neocortex. *Annual review of cell and developmental biology*, 2014, **30**, 38.
30. Bachmann, C., Nguyen, H., Rosenbusch, J., Pham, L., Rabe, T., Patwa, M., Sokpor, G., Seong, R.H., Ashery-Padan, R., Mansouri, A., Stoykova, A., Staiger, J.F. and Tuoc, T., Mswi/snf (baf) complexes are indispensable for the neurogenesis and development of embryonic olfactory epithelium. *PLoS Genet*, 2016, **12**, e1006274.
31. Tuoc, T.C., Boretius, S., Sansom, S.N., Pitulescu, M.E., Frahm, J., Livesey, F.J. and Stoykova, A., Chromatin regulation by baf170 controls cerebral cortical size and thickness. *Dev Cell*, 2013, **25**, 256-269.
32. Van Houdt, J.K., Nowakowska, B.A., Sousa, S.B., van Schaik, B.D., Seuntjens, E., Avonce, N., Sifrim, A., Abdul-Rahman, O.A., van den Boogaard, M.J., Bottani, A., Castori, M., Cormier-Daire, V., Deardorff, M.A., Filges, I., Fryer, A., Fryns, J.P., Gana, S., Garavelli, L., Gillesen-Kaesbach, G., Hall, B.D., Horn, D., Huylebroeck, D., Klapecki, J., Krajewska-Walasek, M., Kuechler, A., Lines, M.A., Maas, S., Macdermot, K.D., McKee, S., Magee, A., de Man, S.A., Moreau, Y., Morice-Picard, F., Obersztyn, E., Pilch, J., Rosser, E., Shannon, N., Stolte-Dijkstra, I., Van Dijck, P., Vilain, C., Vogels, A., Wakeling, E., Wieczorek, D., Wilson, L., Zuffardi, O., van Kampen, A.H., Devriendt, K., Hennekam, R. and Vermeesch, J.R., Heterozygous missense mutations in smarca2 cause nicolaidis-baraitser syndrome. *Nat Genet*, 2012, **44**, 445-449, S441.
33. Biegel, J.A., Zhou, J.Y., Rorke, L.B., Stenstrom, C., Wainwright, L.M. and Fogelgren, B., Germ-line and acquired mutations of ini1 in atypical teratoid and rhabdoid tumors. *Cancer Res*, 1999, **59**, 74-79.

34. Versteeg, I., Sevenet, N., Lange, J., Rousseau-Merck, M.F., Ambros, P., Handgretinger, R., Aurias, A. and Delattre, O., Truncating mutations of *hsnf5/ini1* in aggressive paediatric cancer. *Nature*, 1998, **394**, 203-206.
35. Roberts, C.W., Leroux, M.M., Fleming, M.D. and Orkin, S.H., Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene *snf5*. *Cancer Cell*, 2002, **2**, 415-425.
36. Eaton, K.W., Tooke, L.S., Wainwright, L.M., Judkins, A.R. and Biegel, J.A., Spectrum of *smarcb1/ini1* mutations in familial and sporadic rhabdoid tumors. *Pediatr Blood Cancer*, 2011, **56**, 7-15.
37. Kadoch, C. and Crabtree, G.R., Mammalian *swi/snf* chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Sci Adv*, 2015, **1**, e1500447.
38. Shain, A.H. and Pollack, J.R., The spectrum of *swi/snf* mutations, ubiquitous in human cancers. *PLoS One*, 2013, **8**, e55119.
39. Zehir, A., Benayed, R., Shah, R.H., Syed, A., Middha, S., Kim, H.R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S.M., Hellmann, M.D., Barron, D.A., Schram, A.M., Hameed, M., Dogan, S., Ross, D.S., Hechtman, J.F., Delair, D.F., Yao, J., Mandelker, D.L., Cheng, D.T., Chandramohan, R., Mohanty, A.S., Ptashkin, R.N., Jayakumar, G., Prasad, M., Syed, M.H., Rema, A.B., Liu, Z.Y., Nafa, K., Borsu, L., Sadowska, J., Casanova, J., Bacares, R., Kiecka, I.J., Razumova, A., Son, J.B., Stewart, L., Baldi, T., Mullaney, K.A., Al-Ahmadie, H., Vakiani, E., Abeshouse, A.A., Penson, A.V., Jonsson, P., Camacho, N., Chang, M.T., Won, H.H., Gross, B.E., Kundra, R., Heins, Z.J., Chen, H.W., Phillips, S., Zhang, H., Wang, J., Ochoa, A., Wills, J., Eubank, M., Thomas, S.B., Gardos, S.M., Reales, D.N., Galle, J., Durany, R., Cambria, R., Abida, W., Cercek, A., Feldman, D.R., Gounder, M.M., Hakimi, A.A., Harding, J.J., Iyer, G., Janjigian, Y.Y., Jordan, E.J., Kelly, C.M., Lowery, M.A., Morris, L.G.T., Omuro, A.M., Raj, N., Razavi, P., Shoushtari, A.N., Shukla, N., Soumerai, T.E., Varghese, A.M., Yaeger, R., Coleman, J., Bochner, B., Riely, G.J., Saltz, L.B., Scher, H.I., Sabbatini, P.J., Robson, M.E., Klimstra, D.S., Taylor, B.S., Baselga, J., Schultz, N., Hyman, D.M., Arcila, M.E., Solit, D.B., Ladanyi, M. and Berger, M.F., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*, 2017, **23**, 703-713.
40. Maslah-Planchon, J.B., I.; Gindbretiere, J. -M.; Bourdeaut, F.; Delattre, O., *Swi/snf* chromatin remodeling and human malignancies. *Annual review of Pathology*, 2015, **10**, 27.
41. Wu, J., He, K., Zhang, Y., Song, J., Shi, Z., Chen, W. and Shao, Y., Inactivation of *smarca2* by promoter hypermethylation drives lung cancer development. *Gene*, 2018, **687**, 193-199.
42. Marquez, S.B., Thompson, K.W., Lu, L. and Reisman, D., Beyond mutations: Additional mechanisms and implications of *swi/snf* complex inactivation. *Front Oncol*, 2014, **4**, 372.
43. Khursheed, M., Kolla, J.N., Kotapalli, V., Gupta, N., Gowrishankar, S., Uppin, S.G., Sastry, R.A., Koganti, S., Sundaram, C., Pollack, J.R. and Bashyam, M.D., *Arid1b*, a member of the human *swi/snf* chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. *Br J Cancer*, 2013, **108**, 2056-2062.
44. Trouche, D., Le Chalony, C., Muchardt, C., Yaniv, M. and Kouzarides, T., Rb and hbrm cooperate to repress the activation functions of *e2f1*. *Proc Natl Acad Sci U S A*, 1997, **94**, 11268-11273.
45. Cheng, S.W., Davies, K.P., Yung, E., Beltran, R.J., Yu, J. and Kalpana, G.V., C-myc interacts with *ini1/hsnf5* and requires the *swi/snf* complex for transactivation function. *Nat Genet*, 1999, **22**, 102-105.
46. Lee, D., Kim, J.W., Seo, T., Hwang, S.G., Choi, E.J. and Choe, J., *Swi/snf* complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. *J Biol Chem*, 2002, **277**, 22330-22337.
47. Oh, J., Sohn, D.H., Ko, M., Chung, H., Jeon, S.H. and Seong, R.H., Baf60a interacts with p53 to recruit the *swi/snf* complex. *J Biol Chem*, 2008, **283**, 11924-11934.
48. Xu, Y., Yan, W. and Chen, X., *Snf5*, a core component of the *swi/snf* complex, is necessary for p53 expression and cell survival, in part through *eif4e*. *Oncogene*, 2010, **29**, 4090-4100.
49. Guan, B., Wang, T.L. and Shih Ie, M., *Arid1a*, a factor that promotes formation of *swi/snf*-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. *Cancer Res*, 2011, **71**, 6718-6727.

50. Naidu, S.R., Love, I.M., Imbalzano, A.N., Grossman, S.R. and Androphy, E.J., The swi/snf chromatin remodeling subunit brg1 is a critical regulator of p53 necessary for proliferation of malignant cells. *Oncogene*, 2009, **28**, 2492-2501.
51. Betz, B.L., Strobeck, M.W., Reisman, D.N., Knudsen, E.S. and Weissman, B.E., Re-expression of hsnf5/ini1/baf47 in pediatric tumor cells leads to g1 arrest associated with induction of p16ink4a and activation of rb. *Oncogene*, 2002, **21**, 5193-5203.
52. Inoue, H., Giannakopoulos, S., Parkhurst, C.N., Matsumura, T., Kono, E.A., Furukawa, T. and Tanese, N., Target genes of the largest human swi/snf complex subunit control cell growth. *Biochem J*, 2011, **434**, 83-92.
53. Tordella, L., Khan, S., Hohmeyer, A., Banito, A., Klotz, S., Raguz, S., Martin, N., Dhamarlingam, G., Carroll, T., Gonzalez Meljem, J.M., Deswal, S., Martinez-Barbera, J.P., Garcia-Escudero, R., Zuber, J., Zender, L. and Gil, J., Swi/snf regulates a transcriptional program that induces senescence to prevent liver cancer. *Genes Dev*, 2016, **30**, 2187-2198.
54. Xi, Q., He, W., Zhang, X.H., Le, H.V. and Massague, J., Genome-wide impact of the brg1 swi/snf chromatin remodeler on the transforming growth factor beta transcriptional program. *J Biol Chem*, 2008, **283**, 1146-1155.
55. Ross, S., Cheung, E., Petrakis, T.G., Howell, M., Kraus, W.L. and Hill, C.S., Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. *EMBO J*, 2006, **25**, 4490-4502.
56. Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Koellhoffer, E.C., Pomeroy, S.L., Orkin, S.H. and Roberts, C.W., Epigenetic antagonism between polycomb and swi/snf complexes during oncogenic transformation. *Cancer Cell*, 2010, **18**, 316-328.
57. Kim, K.H. and Roberts, C.W., Mechanisms by which smarcb1 loss drives rhabdoid tumor growth. *Cancer Genet*, 2014, **207**, 365-372.
58. Kohashi, K. and Oda, Y., Oncogenic roles of smarcb1/ini1 and its deficient tumors. *Cancer Sci*, 2017, **108**, 547-552.
59. Orvis, T., Hepperla, A., Walter, V., Song, S., Simon, J., Parker, J., Wilkerson, M.D., Desai, N., Major, M.B., Hayes, D.N., Davis, I.J. and Weissman, B., Brg1/smarca4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. *Cancer Res*, 2014, **74**, 6486-6498.
60. Vorobyeva, N.E., Soshnikova, N.V., Nikolenko, J.V., Kuzmina, J.L., Nabirochkina, E.N., Georgieva, S.G. and Shidlovskii, Y.V., Transcription coactivator sayp combines chromatin remodeler brahma and transcription initiation factor tfiid into a single supercomplex. *Proc Natl Acad Sci U S A*, 2009, **106**, 11049-11054.
61. Alver, B.H., Kim, K.H., Lu, P., Wang, X., Manchester, H.E., Wang, W., Haswell, J.R., Park, P.J. and Roberts, C.W., The swi/snf chromatin remodelling complex is required for maintenance of lineage specific enhancers. *Nat Commun*, 2017, **8**, 14648.
62. Alexander, J.M., Hota, S.K., He, D., Thomas, S., Ho, L., Pennacchio, L.A. and Bruneau, B.G., Brg1 modulates enhancer activation in mesoderm lineage commitment. *Development*, 2015, **142**, 1418-1430.
63. Bossen, C., Murre, C.S., Chang, A.N., Mansson, R., Rodewald, H.R. and Murre, C., The chromatin remodeler brg1 activates enhancer repertoires to establish b cell identity and modulate cell growth. *Nat Immunol*, 2015, **16**, 775-784.
64. Yu, Y., Chen, Y., Kim, B., Wang, H., Zhao, C., He, X., Liu, L., Liu, W., Wu, L.M., Mao, M., Chan, J.R., Wu, J. and Lu, Q.R., Olig2 targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation. *Cell*, 2013, **152**, 248-261.
65. Mathur, R., Alver, B.H., San Roman, A.K., Wilson, B.G., Wang, X., Agoston, A.T., Park, P.J., Shivdasani, R.A. and Roberts, C.W., Arid1a loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. *Nat Genet*, 2017, **49**, 296-302.
66. Wang, X., Lee, R.S., Alver, B.H., Haswell, J.R., Wang, S., Mieczkowski, J., Drier, Y., Gillespie, S.M., Archer, T.C., Wu, J.N., Tzvetkov, E.P., Troisi, E.C., Pomeroy, S.L., Biegel, J.A., Tolstorukov, M.Y., Bernstein,

- B.E., Park, P.J. and Roberts, C.W., Smarcb1-mediated swi/snf complex function is essential for enhancer regulation. *Nat Genet*, 2017, **49**, 289-295.
67. Shanbhag, N.M., Rafalska-Metcalf, I.U., Balane-Bolivar, C., Janicki, S.M. and Greenberg, R.A., Atm-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. *Cell*, 2010, **141**, 970-981.
68. Meisenberg, C., Pinder, S.I., Hopkins, S.R., Wooller, S.K., Benstead-Hume, G., Pearl, F.M.G., Jeggo, P.A. and Downs, J.A., Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. *Mol Cell*, 2019, **73**, 212-223 e217.
69. Tripathy, D., Slamon, D.J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J.E., Murphy, M. and Stewart, S.J., Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. *J Clin Oncol*, 2004, **22**, 1063-1070.
70. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J. and Haber, D.A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, **350**, 2129-2139.
71. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E. and Meyerson, M., Egr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science*, 2004, **304**, 1497-1500.
72. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M. and Varmus, H., Egf receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*, 2004, **101**, 13306-13311.
73. Shaw, A.T. and Engelman, J.A., Alk in lung cancer: Past, present, and future. *J Clin Oncol*, 2013, **31**, 1105-1111.
74. Wiegand, K.C., Shah, S.P., Al-Agha, O.M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M.K., Anglesio, M.S., Kalloger, S.E., Yang, W., Heravi-Moussavi, A., Giuliany, R., Chow, C., Fee, J., Zayed, A., Prentice, L., Melnyk, N., Turashvili, G., Delaney, A.D., Madore, J., Yip, S., McPherson, A.W., Ha, G., Bell, L., Fereday, S., Tam, A., Galletta, L., Tonin, P.N., Provencher, D., Miller, D., Jones, S.J., Moore, R.A., Morin, G.B., Oloumi, A., Boyd, N., Aparicio, S.A., Shih Ie, M., Mes-Masson, A.M., Bowtell, D.D., Hirst, M., Gilks, B., Marra, M.A. and Huntsman, D.G., Arid1a mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med*, 2010, **363**, 1532-1543.
75. Jones, S., Wang, T.L., Shih Ie, M., Mao, T.L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L.A., Jr., Vogelstein, B., Kinzler, K.W., Velculescu, V.E. and Papadopoulos, N., Frequent mutations of chromatin remodeling gene arid1a in ovarian clear cell carcinoma. *Science*, 2010, **330**, 228-231.
76. Rodriguez-Nieto, S., Canada, A., Pros, E., Pinto, A.I., Torres-Lanzas, J., Lopez-Rios, F., Sanchez-Verde, L., Pisano, D.G. and Sanchez-Cespedes, M., Massive parallel DNA pyrosequencing analysis of the tumor suppressor brg1/smarca4 in lung primary tumors. *Hum Mutat*, 2011, **32**, E1999-2017.
77. Lee, R.S., Stewart, C., Carter, S.L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M.S., Auclair, D., Mora, J., Golub, T.R., Biegel, J.A., Getz, G. and Roberts, C.W., A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. *J Clin Invest*, 2012, **122**, 2983-2988.
78. Bultman, S.J., Herschkowitz, J.I., Godfrey, V., Gebuhr, T.C., Yaniv, M., Perou, C.M. and Magnuson, T., Characterization of mammary tumors from brg1 heterozygous mice. *Oncogene*, 2008, **27**, 460-468.
79. Guidi, C.J., Sands, A.T., Zambrowicz, B.P., Turner, T.K., Demers, D.A., Webster, W., Smith, T.W., Imbalzano, A.N. and Jones, S.N., Disruption of ini1 leads to peri-implantation lethality and tumorigenesis in mice. *Mol Cell Biol*, 2001, **21**, 3598-3603.

80. Klochendler-Yeivin, A., Fiette, L., Barra, J., Muchardt, C., Babinet, C. and Yaniv, M., The murine snf5/ini1 chromatin remodeling factor is essential for embryonic development and tumor suppression. *EMBO Rep*, 2000, **1**, 500-506.
81. Lickert, H., Takeuchi, J.K., Von Both, I., Walls, J.R., McAuliffe, F., Adamson, S.L., Henkelman, R.M., Wrana, J.L., Rossant, J. and Bruneau, B.G., Baf60c is essential for function of baf chromatin remodelling complexes in heart development. *Nature*, 2004, **432**, 107-112.
82. Wang, X., Sansam, C.G., Thom, C.S., Metzger, D., Evans, J.A., Nguyen, P.T. and Roberts, C.W., Oncogenesis caused by loss of the snf5 tumor suppressor is dependent on activity of brg1, the atpase of the swi/snf chromatin remodeling complex. *Cancer Res*, 2009, **69**, 8094-8101.
83. Doan, D.N., Veal, T.M., Yan, Z., Wang, W., Jones, S.N. and Imbalzano, A.N., Loss of the ini1 tumor suppressor does not impair the expression of multiple brg1-dependent genes or the assembly of swi/snf enzymes. *Oncogene*, 2004, **23**, 3462-3473.
84. Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., Romero, R., Ramadan, N., Phadke, T., Haas, K., Jaskelioff, M., Wilson, B.G., Meyer, M.J., Saenz-Vash, V., Zhai, H., Myer, V.E., Porter, J.A., Keen, N., McLaughlin, M.E., Mickanin, C., Roberts, C.W., Stegmeier, F. and Jagani, Z., Functional epigenetics approach identifies brm/smarca2 as a critical synthetic lethal target in brg1-deficient cancers. *Proc Natl Acad Sci U S A*, 2014, **111**, 3128-3133.
85. Helming, K.C., Wang, X., Wilson, B.G., Vazquez, F., Haswell, J.R., Manchester, H.E., Kim, Y., Kryukov, G.V., Ghandi, M., Aguirre, A.J., Jagani, Z., Wang, Z., Garraway, L.A., Hahn, W.C. and Roberts, C.W., Arid1b is a specific vulnerability in arid1a-mutant cancers. *Nat Med*, 2014, **20**, 251-254.
86. Wilson, B.G., Helming, K.C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W.C. and Roberts, C.W., Residual complexes containing smarca2 (brm) underlie the oncogenic drive of smarca4 (brg1) mutation. *Mol Cell Biol*, 2014, **34**, 1136-1144.
87. Dutta, A., Sardi, M., Gogol, M., Gilmore, J., Zhang, D., Florens, L., Abmayr, S.M., Washburn, M.P. and Workman, J.L., Composition and function of mutant swi/snf complexes. *Cell Rep*, 2017, **18**, 2124-2134.
88. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. and Cavalli, G., Genome regulation by polycomb and trithorax proteins. *Cell*, 2007, **128**, 735-745.
89. Kia, S.K., Gorski, M.M., Giannakopoulos, S. and Verrijzer, C.P., Swi/snf mediates polycomb eviction and epigenetic reprogramming of the ink4b-arf-ink4a locus. *Mol Cell Biol*, 2008, **28**, 3457-3464.
90. Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., Richon, V.M., Pollock, R.M., Kuntz, K.W. and Keilhack, H., Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase ezh2. *Proc Natl Acad Sci U S A*, 2013, **110**, 7922-7927.
91. Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, M., Conejo-Garcia, J.R., Speicher, D.W. and Zhang, R., Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, 2015, **21**, 231-238.
92. Bitler, B.G., Fatkhutdinov, N. and Zhang, R., Potential therapeutic targets in arid1a-mutated cancers. *Expert Opin Ther Targets*, 2015, **19**, 1419-1422.
93. Tamkun, J.W., Dearing, R., Scott, M.P., Kissinger, M., Pattatucci, A.M., Kaufman, T.C. and Kennison, J.A., Brahma: A regulator of drosophila homeotic genes structurally related to the yeast transcriptional activator snf2/swi2. *Cell*, 1992, **68**, 561-572.
94. Ho, L., Miller, E.L., Ronan, J.L., Ho, W.Q., Jothi, R. and Crabtree, G.R., Esbf facilitates pluripotency by conditioning the genome for lif/stat3 signalling and by regulating polycomb function. *Nat Cell Biol*, 2011, **13**, 903-913.
95. Fillmore, C.M., Xu, C., Desai, P.T., Berry, J.M., Rowbotham, S.P., Lin, Y.J., Zhang, H., Marquez, V.E., Hammerman, P.S., Wong, K.K. and Kim, C.F., Ezh2 inhibition sensitizes brg1 and egfr mutant lung tumours to topoi inhibitors. *Nature*, 2015, **520**, 239-242.

96. Tagal, V., Wei, S., Zhang, W., Brekken, R.A., Posner, B.A., Peyton, M., Girard, L., Hwang, T., Wheeler, D.A., Minna, J.D., White, M.A., Gazdar, A.F. and Roth, M.G., Smarca4-inactivating mutations increase sensitivity to aurora kinase a inhibitor vx-680 in non-small cell lung cancers. *Nat Commun*, 2017, **8**, 14098.
97. Deribe, Y.L., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R.A., Khor, T., Feng, N., Lin, Y.H., Wu, C.C., Reyes, C., Peng, Q., Robinson, F., Inoue, A., Kochat, V., Liu, C.G., Asara, J.M., Moran, C., Muller, F., Wang, J., Fang, B., Papadimitrakopoulou, V., Wistuba, II, Rai, K., Marszalek, J. and Futreal, P.A., Author correction: Mutations in the swi/snf complex induce a targetable dependence on oxidative phosphorylation in lung cancer. *Nat Med*, 2018, **24**, 1627.
98. Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih Ie, M., Uray, I.P., Wu, X., Brown, P.H., Shen, X., Mills, G.B. and Peng, G., Arid1a deficiency impairs the DNA damage checkpoint and sensitizes cells to parp inhibitors. *Cancer Discov*, 2015, **5**, 752-767.
99. Ribeiro-Silva, C., Aydin, O.Z., Mesquita-Ribeiro, R., Slyskova, J., Helfricht, A., Marteiijn, J.A., Hoeijmakers, J.H.J., Lans, H. and Vermeulen, W., DNA damage sensitivity of swi/snf-deficient cells depends on tfiih subunit p62/gtf2h1. *Nat Commun*, 2018, **9**, 4067.
100. Berns, K., Caumanns, J.J., Hijmans, E.M., Gennissen, A.M.C., Severson, T.M., Evers, B., Wisman, G.B.A., Jan Meersma, G., Liefstink, C., Beijersbergen, R.L., Itamochi, H., van der Zee, A.G.J., de Jong, S. and Bernards, R., Arid1a mutation sensitizes most ovarian clear cell carcinomas to bet inhibitors. *Oncogene*, 2018, **37**, 4611-4625.
101. Miller, R.E., Brough, R., Bajrami, I., Williamson, C.T., McDade, S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H., Natrajan, R., Joel, J., Astley, H., Mahoney, C., Moore, J.D., Torrance, C., Gordan, J.D., Webber, J.T., Levin, R.S., Shokat, K.M., Bandyopadhyay, S., Lord, C.J. and Ashworth, A., Synthetic lethal targeting of arid1a-mutant ovarian clear cell tumors with dasatinib. *Mol Cancer Ther*, 2016, **15**, 1472-1484.
102. Bitler, B.G., Wu, S., Park, P.H., Hai, Y., Aird, K.M., Wang, Y., Zhai, Y., Kossenkov, A.V., Vara-Ailor, A., Rauscher, F.J., III, Zou, W., Speicher, D.W., Huntsman, D.G., Conejo-Garcia, J.R., Cho, K.R., Christianson, D.W. and Zhang, R., Arid1a-mutated ovarian cancers depend on hdac6 activity. *Nat Cell Biol*, 2017, **19**, 962-973.
103. Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z.D., Zou, J., Wang, C., Kapoor, P., Ma, X., Ma, D., Liang, J., Song, S., Liu, J., Samson, L.D., Ajani, J.A., Li, G.M., Liang, H., Shen, X., Mills, G.B. and Peng, G., Arid1a deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. *Nat Med*, 2018, **24**, 556-562.
104. Chang, L., Azzolin, L., Di Biagio, D., Zanconato, F., Battilana, G., Lucon Xiccato, R., Aragona, M., Giulitti, S., Panciera, T., Gandin, A., Sigismondo, G., Krijgsveld, J., Fassan, M., Brusatin, G., Cordenonsi, M. and Piccolo, S., The swi/snf complex is a mechanoregulated inhibitor of yap and taz. *Nature*, 2018, **563**, 265-269.
105. Li, X.S., Trojer, P., Matsumura, T., Treisman, J.E. and Tanese, N., Mammalian swi/snf--a subunit baf250/arid1 is an e3 ubiquitin ligase that targets histone h2b. *Mol Cell Biol*, 2010, **30**, 1673-1688.
106. Shi, J., Whyte, W.A., Zepeda-Mendoza, C.J., Milazzo, J.P., Shen, C., Roe, J.S., Minder, J.L., Mercan, F., Wang, E., Eckersley-Maslin, M.A., Campbell, A.E., Kawaoka, S., Shareef, S., Zhu, Z., Kendall, J., Muhar, M., Haslinger, C., Yu, M., Roeder, R.G., Wigler, M.H., Blobel, G.A., Zuber, J., Spector, D.L., Young, R.A. and Vakoc, C.R., Role of swi/snf in acute leukemia maintenance and enhancer-mediated myc regulation. *Genes Dev*, 2013, **27**, 2648-2662.
107. Watanabe, T., Semba, S. and Yokozaki, H., Regulation of pten expression by the swi/snf chromatin-remodelling protein brg1 in human colorectal carcinoma cells. *Br J Cancer*, 2011, **104**, 146-154.
108. Sun, A., Tawfik, O., Gayed, B., Thrasher, J.B., Hoestje, S., Li, C. and Li, B., Aberrant expression of swi/snf catalytic subunits brg1/brm is associated with tumor development and increased invasiveness in prostate cancers. *Prostate*, 2007, **67**, 203-213.

109. Do, S.I., Yoon, G., Kim, H.S., Kim, K., Lee, H., Do, I.G., Kim, D.H., Chae, S.W. and Sohn, J.H., Increased brahma-related gene 1 expression predicts distant metastasis and shorter survival in patients with invasive ductal carcinoma of the breast. *Anticancer Res*, 2016, **36**, 4873-4882.
110. Taulli, R., Foglizzo, V., Morena, D., Coda, D.M., Ala, U., Bersani, F., Maestro, N. and Ponzetto, C., Failure to downregulate the baf53a subunit of the swi/snf chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. *Oncogene*, 2014, **33**, 2354-2362.
111. Meng, L., Wang, X., Liao, W., Liu, J., Liao, Y. and He, Q., Baf53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. *Oncol Rep*, 2017, **38**, 3327-3334.
112. Balasubramaniam, S., Comstock, C.E., Ertel, A., Jeong, K.W., Stallcup, M.R., Addya, S., McCue, P.A., Ostrander, W.F., Jr., Augello, M.A. and Knudsen, K.E., Aberrant baf57 signaling facilitates prometastatic phenotypes. *Clin Cancer Res*, 2013, **19**, 2657-2667.
113. Shen, J., Xiao, Z., Wu, W.K., Wang, M.H., To, K.F., Chen, Y., Yang, W., Li, M.S., Shin, V.Y., Tong, J.H., Kang, W., Zhang, L., Li, M., Wang, L., Lu, L., Chan, R.L., Wong, S.H., Yu, J., Chan, M.T., Chan, F.K., Sung, J.J., Cheng, A.S. and Cho, C.H., Epigenetic silencing of mir-490-3p reactivates the chromatin remodeler smarcd1 to promote helicobacter pylori-induced gastric carcinogenesis. *Cancer Res*, 2015, **75**, 754-765.
114. Heeboll, S., Borre, M., Ottosen, P.D., Andersen, C.L., Mansilla, F., Dyrskjot, L., Orntoft, T.F. and Topping, N., Smarcc1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. *Histol Histopathol*, 2008, **23**, 1069-1076.
115. Buscarlet, M., Krasteva, V., Ho, L., Simon, C., Hebert, J., Wilhelm, B., Crabtree, G.R., Sauvageau, G., Thibault, P. and Lessard, J.A., Essential role of brg, the atpase subunit of baf chromatin remodeling complexes, in leukemia maintenance. *Blood*, 2014, **123**, 1720-1728.
116. Wu, Q., Madany, P., Akech, J., Dobson, J.R., Douthwright, S., Browne, G., Colby, J.L., Winter, G.E., Bradner, J.E., Pratap, J., Sluder, G., Bhargava, R., Chiosea, S.I., van Wijnen, A.J., Stein, J.L., Stein, G.S., Lian, J.B., Nickerson, J.A. and Imbalzano, A.N., The swi/snf atpases are required for triple negative breast cancer cell proliferation. *J Cell Physiol*, 2015, **230**, 2683-2694.
117. Wu, Q., Lian, J.B., Stein, J.L., Stein, G.S., Nickerson, J.A. and Imbalzano, A.N., The brg1 atpase of human swi/snf chromatin remodeling enzymes as a driver of cancer. *Epigenomics*, 2017, **9**, 919-931.
118. Jubierre, L., Soriano, A., Planells-Ferrer, L., Paris-Coderch, L., Tenbaum, S.P., Romero, O.A., Moubarak, R.S., Almazan-Moga, A., Molist, C., Roma, J., Navarro, S., Noguera, R., Sanchez-Cespedes, M., Comella, J.X., Palmer, H.G., Sanchez de Toledo, J., Gallego, S. and Segura, M.F., Brg1/smarca4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. *Oncogene*, 2016, **35**, 5179-5190.
119. Boulay, G., Sandoval, G.J., Riggi, N., Iyer, S., Buisson, R., Naigles, B., Awad, M.E., Rengarajan, S., Volorio, A., McBride, M.J., Broye, L.C., Zou, L., Stamenkovic, I., Kadoch, C. and Rivera, M.N., Cancer-specific retargeting of baf complexes by a prion-like domain. *Cell*, 2017, **171**, 163-178 e119.
120. Guerrero-Martinez, J.A. and Reyes, J.C., High expression of smarca4 or smarca2 is frequently associated with an opposite prognosis in cancer. *Sci Rep*, 2018, **8**, 2043.
121. Kadoch, C. and Crabtree, G.R., Reversible disruption of mswi/snf (baf) complexes by the ss18-ssx oncogenic fusion in synovial sarcoma. *Cell*, 2013, **153**, 71-85.
122. McBride, M.J., Pulice, J.L., Beird, H.C., Ingram, D.R., D'Avino, A.R., Shern, J.F., Charville, G.W., Hornick, J.L., Nakayama, R.T., Garcia-Rivera, E.M., Araujo, D.M., Wang, W.L., Tsai, J.W., Yeagley, M., Wagner, A.J., Futreal, P.A., Khan, J., Lazar, A.J. and Kadoch, C., The ss18-ssx fusion oncoprotein hijacks baf complex targeting and function to drive synovial sarcoma. *Cancer Cell*, 2018, **33**, 1128-1141 e1127.
123. Pfister, N.T., Fomin, V., Regunath, K., Zhou, J.Y., Zhou, W., Silwal-Pandit, L., Freed-Pastor, W.A., Laptenko, O., Neo, S.P., Bargonetti, J., Hoque, M., Tian, B., Gunaratne, J., Engebraaten, O., Manley, J.L., Borresen-Dale, A.L., Neilsen, P.M. and Prives, C., Mutant p53 cooperates with the swi/snf chromatin remodeling complex to regulate vegfr2 in breast cancer cells. *Genes Dev*, 2015, **29**, 1298-1315.

124. Wang, G., Fu, Y., Hu, F., Lan, J., Xu, F., Yang, X., Luo, X., Wang, J. and Hu, J., Loss of brg1 induces crc cell senescence by regulating p53/p21 pathway. *Cell Death Dis*, 2017, **8**, e2607.
125. Robinson, G., Parker, M., Kranenburg, T.A., Lu, C., Chen, X., Ding, L., Phoenix, T.N., Hedlund, E., Wei, L., Zhu, X., Chalhoub, N., Baker, S.J., Huether, R., Kriwacki, R., Curley, N., Thiruvengadam, R., Wang, J., Wu, G., Rusch, M., Hong, X., Becksfort, J., Gupta, P., Ma, J., Easton, J., Vadodaria, B., Onar-Thomas, A., Lin, T., Li, S., Pounds, S., Paugh, S., Zhao, D., Kawachi, D., Roussel, M.F., Finkelstein, D., Ellison, D.W., Lau, C.C., Bouffet, E., Hassall, T., Gururangan, S., Cohn, R., Fulton, R.S., Fulton, L.L., Dooling, D.J., Ochoa, K., Gajjar, A., Mardis, E.R., Wilson, R.K., Downing, J.R., Zhang, J. and Gilbertson, R.J., Novel mutations target distinct subgroups of medulloblastoma. *Nature*, 2012, **488**, 43-48.
126. Pugh, T.J., Weeraratne, S.D., Archer, T.C., Pomeranz Krummel, D.A., Auclair, D., Bochicchio, J., Carneiro, M.O., Carter, S.L., Cibulskis, K., Erlich, R.L., Greulich, H., Lawrence, M.S., Lennon, N.J., McKenna, A., Meldrim, J., Ramos, A.H., Ross, M.G., Russ, C., Shefler, E., Sivachenko, A., Sogoloff, B., Stojanov, P., Tamayo, P., Mesirov, J.P., Amani, V., Teider, N., Sengupta, S., Francois, J.P., Northcott, P.A., Taylor, M.D., Yu, F., Crabtree, G.R., Kautzman, A.G., Gabriel, S.B., Getz, G., Jager, N., Jones, D.T., Lichter, P., Pfister, S.M., Roberts, T.M., Meyerson, M., Pomeroy, S.L. and Cho, Y.J., Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*, 2012, **488**, 106-110.
127. Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y., Kaname, T., Naritomi, K., Kawame, H., Wakui, K., Fukushima, Y., Homma, T., Kato, M., Hiraki, Y., Yamagata, T., Yano, S., Mizuno, S., Sakazume, S., Ishii, T., Nagai, T., Shiina, M., Ogata, K., Ohta, T., Niikawa, N., Miyatake, S., Okada, I., Mizuguchi, T., Doi, H., Saitsu, H., Miyake, N. and Matsumoto, N., Mutations affecting components of the swi/snf complex cause coffin-siris syndrome. *Nat Genet*, 2012, **44**, 376-378.
128. Backx, L., Seuntjens, E., Devriendt, K., Vermeesch, J. and Van Esch, H., A balanced translocation t(6;14)(q25.3;q13.2) leading to reciprocal fusion transcripts in a patient with intellectual disability and agenesis of corpus callosum. *Cytogenet Genome Res*, 2011, **132**, 135-143.
129. Halgren, C., Kjaergaard, S., Bak, M., Hansen, C., El-Schich, Z., Anderson, C.M., Henriksen, K.F., Hjalgrim, H., Kirchhoff, M., Bijlsma, E.K., Nielsen, M., den Hollander, N.S., Ruivenkamp, C.A., Isidor, B., Le Caignec, C., Zannolli, R., Mucciolo, M., Renieri, A., Mari, F., Anderlid, B.M., Andrieux, J., Dieux, A., Tommerup, N. and Bache, I., Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of arid1b. *Clin Genet*, 2012, **82**, 248-255.
130. Takenouchi, T., Yoshihashi, H., Sakaguchi, Y., Uehara, T., Honda, M., Takahashi, T., Kosaki, K. and Miyama, S., Hirschsprung disease as a yet undescribed phenotype in a patient with arid1b mutation. *Am J Med Genet A*, 2016, **170**, 3249-3252.
131. Santen, G.W., Aten, E., Sun, Y., Almomani, R., Gilissen, C., Nielsen, M., Kant, S.G., Snoeck, I.N., Peeters, E.A., Hilhorst-Hofstee, Y., Wessels, M.W., den Hollander, N.S., Ruivenkamp, C.A., van Ommen, G.J., Breuning, M.H., den Dunnen, J.T., van Haeringen, A. and Kriek, M., Mutations in swi/snf chromatin remodeling complex gene arid1b cause coffin-siris syndrome. *Nat Genet*, 2012, **44**, 379-380.
132. Bramswig, N.C., Caluseriu, O., Ludecke, H.J., Bolduc, F.V., Noel, N.C., Wieland, T., Surowy, H.M., Christen, H.J., Engels, H., Strom, T.M. and Wiczorek, D., Heterozygosity for arid2 loss-of-function mutations in individuals with a coffin-siris syndrome-like phenotype. *Hum Genet*, 2017, **136**, 297-305.
133. Koga, M., Ishiguro, H., Yazaki, S., Horiuchi, Y., Arai, M., Niizato, K., Iritani, S., Itokawa, M., Inada, T., Iwata, N., Ozaki, N., Ujike, H., Kunugi, H., Sasaki, T., Takahashi, M., Watanabe, Y., Someya, T., Kakita, A., Takahashi, H., Nawa, H., Muchardt, C., Yaniv, M. and Arinami, T., Involvement of smarca2/brm in the swi/snf chromatin-remodeling complex in schizophrenia. *Hum Mol Genet*, 2009, **18**, 2483-2494.
134. Tang, S., Hughes, E., Lascelles, K., Euro, E.R.E.S.m.a.e.w.g., Simpson, M.A. and Pal, D.K., New smarca2 mutation in a patient with nicolaides-baraitser syndrome and myoclonic astatic epilepsy. *Am J Med Genet A*, 2017, **173**, 195-199.

135. Wolff, D., Endeley, S., Azzarello-Burri, S., Hoyer, J., Zweier, M., Schanze, I., Schmitt, B., Rauch, A., Reis, A. and Zweier, C., In-frame deletion and missense mutations of the c-terminal helicase domain of *smarca2* in three patients with nicolaides-baraitser syndrome. *Mol Syndromol*, 2012, **2**, 237-244.
136. De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Cicek, A.E., Kou, Y., Liu, L., Fromer, M., Walker, S., Singh, T., Klei, L., Kosmicki, J., Shih-Chen, F., Aleksic, B., Biscaldi, M., Bolton, P.F., Brownfeld, J.M., Cai, J., Campbell, N.G., Carracedo, A., Chahrour, M.H., Chiochetti, A.G., Coon, H., Crawford, E.L., Curran, S.R., Dawson, G., Duketis, E., Fernandez, B.A., Gallagher, L., Geller, E., Guter, S.J., Hill, R.S., Ionita-Laza, J., Jimenez Gonzalez, P., Kilpinen, H., Klauck, S.M., Kolevzon, A., Lee, I., Lei, I., Lei, J., Lehtimaki, T., Lin, C.F., Ma'ayan, A., Marshall, C.R., McInnes, A.L., Neale, B., Owen, M.J., Ozaki, N., Parellada, M., Parr, J.R., Purcell, S., Puura, K., Rajagopalan, D., Rehnstrom, K., Reichenberg, A., Sabo, A., Sachse, M., Sanders, S.J., Schafer, C., Schulte-Ruther, M., Skuse, D., Stevens, C., Szatmari, P., Tammimies, K., Valladares, O., Voran, A., Li-San, W., Weiss, L.A., Willsey, A.J., Yu, T.W., Yuen, R.K., Study, D.D.D., Homozygosity Mapping Collaborative for, A., Consortium, U.K., Cook, E.H., Freitag, C.M., Gill, M., Hultman, C.M., Lehner, T., Palotie, A., Schellenberg, G.D., Sklar, P., State, M.W., Sutcliffe, J.S., Walsh, C.A., Scherer, S.W., Zwick, M.E., Barrett, J.C., Cutler, D.J., Roeder, K., Devlin, B., Daly, M.J. and Buxbaum, J.D., Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature*, 2014, **515**, 209-215.
137. Kleefstra, T., Kramer, J.M., Neveling, K., Willemsen, M.H., Koemans, T.S., Vissers, L.E., Wissink-Lindhout, W., Fenckova, M., van den Akker, W.M., Kasri, N.N., Nillesen, W.M., Prescott, T., Clark, R.D., Devriendt, K., van Reeuwijk, J., de Brouwer, A.P., Gilissen, C., Zhou, H., Brunner, H.G., Veltman, J.A., Schenck, A. and van Bokhoven, H., Disruption of an ehmt1-associated chromatin-modification module causes intellectual disability. *Am J Hum Genet*, 2012, **91**, 73-82.
138. Gossai, N., Biegel, J.A., Messiaen, L., Berry, S.A. and Moertel, C.L., Report of a patient with a constitutional missense mutation in *smarcb1*, coffin-siris phenotype, and schwannomatosis. *Am J Med Genet A*, 2015, **167A**, 3186-3191.
139. Wieczorek, D., Bogershausen, N., Beleggia, F., Steiner-Haldenstatt, S., Pohl, E., Li, Y., Milz, E., Martin, M., Thiele, H., Altmuller, J., Alanay, Y., Kayserili, H., Klein-Hitpass, L., Bohringer, S., Wollstein, A., Albrecht, B., Boduroglu, K., Caliebe, A., Chrzanowska, K., Cogulu, O., Cristofoli, F., Czeschik, J.C., Devriendt, K., Dotti, M.T., Elcioglu, N., Gener, B., Goecke, T.O., Krajewska-Walasek, M., Guillen-Navarro, E., Hayek, J., Houge, G., Kilic, E., Simsek-Kiper, P.O., Lopez-Gonzalez, V., Kuechler, A., Lyonnet, S., Mari, F., Marozza, A., Mathieu Dramard, M., Mikat, B., Morin, G., Morice-Picard, F., Ozkinay, F., Rauch, A., Renieri, A., Tinschert, S., Utine, G.E., Vilain, C., Vivarelli, R., Zweier, C., Nurnberg, P., Rahmann, S., Vermeesch, J., Ludecke, H.J., Zeschning, M. and Wollnik, B., A comprehensive molecular study on coffin-siris and nicolaides-baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. *Hum Mol Genet*, 2013, **22**, 5121-5135.
140. Kosho, T., Okamoto, N. and Coffin-Siris Syndrome International, C., Genotype-phenotype correlation of coffin-siris syndrome caused by mutations in *smarcb1*, *smarca4*, *smarce1*, and *arid1a*. *Am J Med Genet C Semin Med Genet*, 2014, **166C**, 262-275.
141. Zarate, Y.A., Bhoj, E., Kaylor, J., Li, D., Tsurusaki, Y., Miyake, N., Matsumoto, N., Phadke, S., Escobar, L., Irani, A., Hakonarson, H. and Schrier Vergano, S.A., *Smarce1*, a rare cause of coffin-siris syndrome: Clinical description of three additional cases. *Am J Med Genet A*, 2016, **170**, 1967-1973.
142. Neale, B.M., Kou, Y., Liu, L., Ma'ayan, A., Samocha, K.E., Sabo, A., Lin, C.F., Stevens, C., Wang, L.S., Makarov, V., Polak, P., Yoon, S., Maguire, J., Crawford, E.L., Campbell, N.G., Geller, E.T., Valladares, O., Schafer, C., Liu, H., Zhao, T., Cai, G., Lihm, J., Dannenfelser, R., Jabado, O., Peralta, Z., Nagaswamy, U., Muzny, D., Reid, J.G., Newsham, I., Wu, Y., Lewis, L., Han, Y., Voight, B.F., Lim, E., Rossin, E., Kirby, A., Flannick, J., Fromer, M., Shakir, K., Fennell, T., Garimella, K., Banks, E., Poplin, R., Gabriel, S., DePristo, M., Wimbish, J.R., Boone, B.E., Levy, S.E., Betancur, C., Sunyaev, S., Boerwinkle, E., Buxbaum, J.D., Cook, E.H., Jr., Devlin, B., Gibbs, R.A., Roeder, K., Schellenberg, G.D., Sutcliffe, J.S. and Daly, M.J., Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature*, 2012, **485**, 242-245.

143. O'Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee, C., Smith, J.D., Turner, E.H., Stanaway, I.B., Vernot, B., Malig, M., Baker, C., Reilly, B., Akey, J.M., Borenstein, E., Rieder, M.J., Nickerson, D.A., Bernier, R., Shendure, J. and Eichler, E.E., Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature*, 2012, **485**, 246-250.
144. Bagheri, H., Badduke, C., Qiao, Y., Colnaghi, R., Abramowicz, I., Alcantara, D., Dunham, C., Wen, J., Wildin, R.S., Nowaczyk, M.J., Eichmeyer, J., Lehman, A., Maranda, B., Martell, S., Shan, X., Lewis, S.M., O'Driscoll, M., Gregory-Evans, C.Y. and Rajcan-Separovic, E., Identifying candidate genes for 2p15p16.1 microdeletion syndrome using clinical, genomic, and functional analysis. *JCI Insight*, 2016, **1**, e85461.
145. Ratnakumar, K. and Bernstein, E., Atrx: The case of a peculiar chromatin remodeler. *Epigenetics*, 2013, **8**, 3-9.
146. Elizondo, L.I., Cho, K.S., Zhang, W., Yan, J., Huang, C., Huang, Y., Choi, K., Sloan, E.A., Deguchi, K., Lou, S., Baradaran-Heravi, A., Takashima, H., Lucke, T., Quijcho, F.A. and Boerkoel, C.F., Schimke immuno-osseous dysplasia: Smarcal1 loss-of-function and phenotypic correlation. *J Med Genet*, 2009, **46**, 49-59.

Table 1. SWI/SNF proteins from human, Drosophila and Yeast.

Human		Drosophila		Yeast	
BAF	pBAF	BAP	PBAP	SWI/SNF	RSC
BRG1/BRM	BRG1	BRM/Brahma		SWI2/SNF2	Sth1
ARID1A/ ARID1B	ARID2	OSA	BAP170	SWI1/Adr6	Rsc9
	BAF180/ PBRM1		Polybromo		Rsc1,2,4
	BRD7				
INI1/BAF47/SNF5		BAP45/SNR1		Snf5	Sfh1
BAF60a,b,c		BAP60		Swp73	Rsc6
BAF155/170		MMOIRA/BAP155		SWI3	Rsc8/Swh3
beta Actin		Actin		Arp 7,9	
BAF57		BAP111			
BAF53 a,b		BAP55/BAP47			
BAF45 a,b,c,d					

Table 2a. Role of SWI/SNF components in neurological disorders.

Gene name	Mutation type	Syndrome/Symptoms	References
ARID1A	Nonsense, frameshift, indel	Coffin–Siris syndrome	¹²⁷
ARID1B	Translocation, frameshift, indel, nonsense, missense, microdeletion	Coffin–Siris syndrome, autism, Nicolaides-Baraitser syndrome, schizophrenia, Hirschsprung’s disease, Intellectual disability	¹²⁸⁻¹³¹
ARID2	Frameshift, indel	Coffin-Siris syndrome	¹³²
SMARCA2	Partial deletion, missense, intronic alteration, duplication	Coffin-Siris syndrome, Nicolaides-Baraitser syndrome, schizophrenia	¹³³⁻¹³⁵
SMARCA4	Partial deletion, missense	Coffin-Siris syndrome, autism	^{127, 136}
SMARCB1	In-frame deletion, missense	Coffin-Siris syndrome, Kleefstra syndrome phenotypic spectrum	^{127, 137, 138}
SMARCE1	Missense	Coffin-Siris syndrome	¹³⁹⁻¹⁴¹
SMARCC1	Missense	Autism, social deficits and communication difficulties, restricted and repetitive behaviors	¹⁴²
SMARCC2	Splice site mutation	Autism, social deficits and communication difficulties, restricted and repetitive behaviors	¹⁴²
PBRM1	Missense	Autism, social deficits and communication difficulties, restricted and repetitive behaviors	¹⁴³
BCL11A	Micro deletion, missense, and frameshift mutations	2p15–16.1 microdeletion syndrome; autism; schizophrenia	^{136, 144}
ATRX	Missense	ATRX syndrome	¹⁴⁵
SMARCAL1		Schimke immuno osseus dysplasia	¹⁴⁶

Table 2b. Role of SWI/SNF components in cancers.

Gene name	SWI/SNF component	Cancer
SMARCB1	BAF47	Rhabdoid tumors, Epitheloid tumors, Schwannomatosis, Multiple meningiomas
SMARCE1	BAF57	Clear cell meningioma
BRD9		Acute myeloid leukemia
ARID1A	BAF250A	Clear cell ovarian, endometrial, colorectal, stomach, and bladder cancers
ARID1B	BAF250B	Colorectal, pancreatic and breast cancer, and neuroblastoma
BRG1	SMARCA4	Non-small-cell lung carcinoma, burkitt's lymphoma, childhood medulloblastoma, pancreatic adenocarcinoma, ovarian clear cell carcinoma, and melanoma
BRM	SMARCA2	Lung, breast, ovary, bladder and esophagus cancers and pediatric rhabdoid tumors
BAF60a	SMARCD1	Breast
BRD7		Breast cancer, Nasopharyngeal carcinoma
ARID2	BAF200	Melanoma, Hepatocellular carcinoma
PBRM1	BAF180	Clear cell renal cell carcinoma, Pancreatic cancer
SMARCAL1		Schimke immuno osseus dysplasia
SS18:SSX	SS18	Synovial sarcoma

Figure legends

Figure 1. Frequency of SWI/SNF inactivation in various cancers. The mutation frequency was determined from cBioPortal as described in the text. Colour code: green, mutation; red, amplification; blue, deep deletion; purple, fusion; grey, multiple alterations.